NBIX

SEC source: 0001909817-26-000010 · wk-form4_1789506190.xml · nonDerivative · entry 3

Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,722

F4 · kind: The disposition reported on this line was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F5 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $157.31 to $157.5950. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001724097-26-000010 · wk-form4_1789506139.xml · nonDerivative · entry 3

ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 42,808

F3 · kind: The disposition reported on this line was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $157.05 to $157.43. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001894425-26-000020 · wk-form4_1789506418.xml · nonDerivative · entry 2

Onyia Jude · CIK 0001894425 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,647

F2 · kind: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

SEC source: 0001894425-26-000020 · wk-form4_1789506418.xml · nonDerivative · entry 1

Onyia Jude · CIK 0001894425 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,583

F1 · kind: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.

SEC source: 0001504783-26-000019 · wk-form4_1789506394.xml · nonDerivative · entry 2

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,793

F2 · kind: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

SEC source: 0001504783-26-000019 · wk-form4_1789506394.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,212

F1 · kind: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.

SEC source: 0001818524-26-000006 · wk-form4_1789506353.xml · nonDerivative · entry 2

Keswani Sanjay Chandru · CIK 0001818524 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,281

F2 · kind: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

SEC source: 0001818524-26-000006 · wk-form4_1789506353.xml · nonDerivative · entry 1

Keswani Sanjay Chandru · CIK 0001818524 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,393

F1 · kind: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.

SEC source: 0001201096-26-000018 · wk-form4_1789506329.xml · nonDerivative · entry 2

GORMAN KEVIN CHARLES · CIK 0001201096 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 517,797

F2 · kind: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

F3 · balance_after: 517,797 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power.

SEC source: 0001201096-26-000018 · wk-form4_1789506329.xml · nonDerivative · entry 1

GORMAN KEVIN CHARLES · CIK 0001201096 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 525,636

F1 · kind: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.

SEC source: 0001567160-26-000009 · wk-form4_1789506302.xml · nonDerivative · entry 4

Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 154,728

F3 · kind: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

SEC source: 0001567160-26-000009 · wk-form4_1789506302.xml · nonDerivative · entry 3

Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,722

F1 · kind: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.

SEC source: 0001567160-26-000009 · wk-form4_1789506302.xml · nonDerivative · entry 2

Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 153,880

F3 · kind: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

SEC source: 0001567160-26-000009 · wk-form4_1789506302.xml · nonDerivative · entry 1

Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 157,266

F1 · kind: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.

F2 · balance_after: Includes an aggregate of 176 shares purchased on February 27, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.

SEC source: 0001965808-26-000015 · wk-form4_1789506243.xml · nonDerivative · entry 2

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,289

F2 · kind: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

SEC source: 0001965808-26-000015 · wk-form4_1789506243.xml · nonDerivative · entry 1

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,708

F1 · kind: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.

SEC source: 0001776977-26-000013 · wk-form4_1789506221.xml · nonDerivative · entry 2

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,025

F2 · kind: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

F3 · balance_after: 21,985 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power.

SEC source: 0001776977-26-000013 · wk-form4_1789506221.xml · nonDerivative · entry 1

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,961

F1 · kind: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.

SEC source: 0001909817-26-000010 · wk-form4_1789506190.xml · nonDerivative · entry 2

Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,548

F3 · kind: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

SEC source: 0001909817-26-000010 · wk-form4_1789506190.xml · nonDerivative · entry 1

Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,484

F1 · kind: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.

F2 · balance_after: Includes an aggregate of 98 shares purchased on August 31, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.

SEC source: 0001643653-26-000018 · wk-form4_1789506163.xml · nonDerivative · entry 2

BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,297

F2 · kind: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

SEC source: 0001643653-26-000018 · wk-form4_1789506163.xml · nonDerivative · entry 1

BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,683

F1 · kind: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.

SEC source: 0001724097-26-000010 · wk-form4_1789506139.xml · nonDerivative · entry 2

ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,119

F2 · kind: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

SEC source: 0001724097-26-000010 · wk-form4_1789506139.xml · nonDerivative · entry 1

ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,828

F1 · kind: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.

SEC source: 0001643653-26-000016 · wk-form4_1789086545.xml · derivative · entry 3

BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,194 shares

Expires 2027-02-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option was granted February 6, 2017 and vested in 48 equal monthly installments beginning March 6, 2017. These options were due to expire on February 6, 2027.

SEC source: 0001643653-26-000016 · wk-form4_1789086545.xml · nonDerivative · entry 2

BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 64,408

F2 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

SEC source: 0001643653-26-000016 · wk-form4_1789086545.xml · nonDerivative · entry 1

BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 66,562

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes an aggregate of 178 shares purchased on February 27, 2026 and August 31, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.

SEC source: 0001079462-26-000008 · wk-form4_1788485992.xml · nonDerivative · entry 1

SHERWIN STEPHEN A · CIK 0001079462 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,860

F1 · kind: This transaction represents a gift/charitable contribution effective September 2, 2026. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares.

SEC source: 0001894425-26-000018 · wk-form4_1785965748.xml · nonDerivative · entry 1

Onyia Jude · CIK 0001894425 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,996

F1 · kind: This transaction represents a gift/charitable contribution effective August 4, 2026. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares.

SEC source: 0001533568-26-000012 · wk-form4_1785446949.xml · derivative · entry 3

Norwalk Leslie V · CIK 0001533568 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,140

Underlying: Common Stock · 842 shares

Expires 2034-05-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Option vested in 12 monthly installments beginning June 22, 2024.

SEC source: 0001533568-26-000012 · wk-form4_1785446949.xml · nonDerivative · entry 2

Norwalk Leslie V · CIK 0001533568 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,430

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001533568-26-000012 · wk-form4_1785446949.xml · nonDerivative · entry 1

Norwalk Leslie V · CIK 0001533568 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,588

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted and effective on September 15, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $182.00 to $182.03. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001965808-26-000013 · wk-form4_1783974461.xml · derivative · entry 3

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,367 shares

Expires 2031-02-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Option granted February 1, 2021 and vested at 25% upon first anniversary (February 1, 2022) and remaining 75% vested in 36 equal monthly installments beginning on March 1, 2022.

SEC source: 0001965808-26-000013 · wk-form4_1783974461.xml · nonDerivative · entry 2

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,225

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

SEC source: 0001965808-26-000013 · wk-form4_1783974461.xml · nonDerivative · entry 1

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,592

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001965808-26-000011 · wk-form4_1783636859.xml · derivative · entry 9

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,478

Underlying: Common Stock · 8,433 shares

Expires 2033-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option was granted February 13, 2023 and vests in 48 equal monthly installments beginning March 13, 2023.

SEC source: 0001965808-26-000011 · wk-form4_1783636859.xml · nonDerivative · entry 6

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,225

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $178.52 to $179.19. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001965808-26-000011 · wk-form4_1783636859.xml · nonDerivative · entry 5

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,658

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001504783-26-000017 · wk-form4_1783974426.xml · derivative · entry 3

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,965

Underlying: Common Stock · 10,000 shares

Expires 2028-02-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option was granted February 5, 2018 and vested in 48 equal monthly installments beginning March 5, 2018.

SEC source: 0001504783-26-000017 · wk-form4_1783974426.xml · nonDerivative · entry 2

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,729

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $179.50 to $179.80. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001504783-26-000017 · wk-form4_1783974426.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 64,729

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001965808-26-000011 · wk-form4_1783636859.xml · derivative · entry 8

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,911

Underlying: Common Stock · 2,737 shares

Expires 2033-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option was granted February 13, 2023 and vests in 48 equal monthly installments beginning March 13, 2023.

SEC source: 0001965808-26-000011 · wk-form4_1783636859.xml · nonDerivative · entry 4

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,225

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $178.52 to $178.59. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001965808-26-000011 · wk-form4_1783636859.xml · nonDerivative · entry 3

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,962

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001965808-26-000011 · wk-form4_1783636859.xml · derivative · entry 7

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,648

Underlying: Common Stock · 3,401 shares

Expires 2033-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option was granted February 13, 2023 and vests in 48 equal monthly installments beginning March 13, 2023.

SEC source: 0001965808-26-000011 · wk-form4_1783636859.xml · nonDerivative · entry 2

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,225

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $178.52 to $178.75. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001965808-26-000011 · wk-form4_1783636859.xml · nonDerivative · entry 1

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,626

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001504783-26-000015 · wk-form4_1782852730.xml · derivative · entry 9

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,965

Underlying: Common Stock · 1,690 shares

Expires 2028-02-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option was granted February 5, 2018 and vested in 48 equal monthly installments beginning March 5, 2018.

SEC source: 0001504783-26-000015 · wk-form4_1782852730.xml · derivative · entry 8

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,655

Underlying: Common Stock · 8,110 shares

Expires 2028-02-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option was granted February 5, 2018 and vested in 48 equal monthly installments beginning March 5, 2018.

SEC source: 0001504783-26-000015 · wk-form4_1782852730.xml · nonDerivative · entry 6

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,729

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $170.58 to $170.91. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.